Drug DosingABI-5366's PK profile is supportive of once-weekly or once-monthly dosing, which is highly encouraging.
Drug Safety And DosingABI-5366 was safe and well-tolerated with up to 70 days of exposure with healthy volunteers in Phase 1a.
Drug SelectivityABI-6250 showed favorable selectivity for NTCP over other bile acid transporters in preclinical studies.
Oral BioavailabilityABI-6250's oral bioavailability is a key attribute, indicating the potential for once-daily oral dosing, possibly becoming the first oral chronic HDV treatment.
Virology ReadoutsFour 2025 Virology Readouts Provide Multiple Opportunities for Upside.